Arrowhead Pharmaceuticals's EBIT per Share for the
three
months ended in Dec. 2023 was $-1.24.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.64.
During the past 3 years, the average EBIT per Share Growth Rate was -27.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Arrowhead Pharmaceuticals's EBIT per Share or its related term are showing as below:
ARWR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -194.5 Med: 5.7 Max: 74.7
Current: -27.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Arrowhead Pharmaceuticals was 74.70% per year. The lowest was -194.50% per year. And the median was 5.70% per year.
ARWR's 3-Year EBIT Growth Rate is ranked worse than 79.45% of 1304
companies
in the Biotechnology industry
Industry Median: 3.35
vs ARWR: -27.60
Arrowhead Pharmaceuticals's EBIT for the
three
months ended in Dec. 2023 was $-133.3 Mil.
Arrowhead Pharmaceuticals EBIT per Share Historical Data
The historical data trend for Arrowhead Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals (NAS:ARWR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Arrowhead Pharmaceuticals EBIT per Share Related Terms
Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Business Description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARWR has been successfully added to your 